Hudson Bay Capital Management
IMNM icon

Hudson Bay Capital Management’s Immunome IMNM Stock Holding History

Hudson Bay Capital Management’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-119,700
Closed -$1.75M – 1002
2024
Q3 		$1.75M Buy
+119,700
New +$1.7M 0.01% 583

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Hudson Bay Capital Management's IMNM Position: Q4 2024 in Review

Hudson Bay Capital Management sold out of Immunome (IMNM) in Q4 2024, closing a stake of 66,864 shares — an estimated $978K sold.

Hudson Bay Capital Management first reported a position in IMNM in Q3 2024 and held it in 1 quarter. The position peaked at $978K in Q3 2024. 120 funds tracked by Wall St. Rank hold IMNM as of Q4 2024.

  • Hudson Bay Capital Management reported no remaining Immunome position as of Q4 2024 after selling out during the quarter.
  • Hudson Bay Capital Management sold 66,864 Immunome shares in Q4 2024, an estimated $978K.
  • Hudson Bay Capital Management first reported a position in Immunome in Q3 2024 and held it in 1 quarter.
  • Hudson Bay Capital Management's Immunome position peaked at $978K in Q3 2024.
  • 120 funds tracked by Wall St. Rank held Immunome as of Q4 2024.

Based on Hudson Bay Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.